Blood Markers of Blood Vessel Lining Changes in Children With New High Blood Pressure
Compares blood markers of vessel lining activation in children with and without high blood pressure.
Plain-language title generated from the registry record
Registry title: Endothelial Extracellular Vesicles as Biomarkers of Endothelial Activation in Children With Newly Diagnosed Hypertension
Key facts
- Where
- Osijek, CroatiaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and teenagers aged 6-17 years. They either have normal blood pressure or newly diagnosed high blood pressure that has not been treated.
- Age
- 6-17 years
- Sex
- Boys and girls can both join.
- Disease stage
- Normal blood pressure, or newly diagnosed primary high blood pressure that has not been treated before.
- Earlier treatment
- Must not have had blood pressure medicine before.
Main reasons for not taking part
- Secondary high blood pressure
- Heart disease present from birth, or other major heart or blood vessel disease
- Diabetes, chronic kidney disease, autoimmune or long-term inflammatory disease, or cancer
- Acute infection at the time of enrolment
- Taking medicines known to affect the lining of the blood vessels
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 6 and 17 years old?
Source: NCT07728643, who can take part
Where in Croatia
- Faculty of Medicine OsijekOsijek, CroatiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Josip Juraj Strossmayer University of Osijek
- Trial code
- NCT07728643
- Record updated
- 27 July 2026
- Original description
Childhood hypertension is associated with early endothelial dysfunction and an increased risk of future cardiovascular disease. Endothelial extracellular vesicles (EEVs) have emerged as promising biomarkers of endothelial activation; however, their role in pediatric hypertension remains poorly understood. This observational case-control study aims to compare circulating EEV concentrations between normotensive children and children with newly diagnosed, untreated primary hypertension. The study will also investigate the associations between EEV levels, blood pressure, microvascular endothelial function assessed by laser Doppler flowmetry, and circulating biomarkers of endothelial activation. The findings may improve understanding of endothelial injury in pediatric hypertension and support the development of non-invasive biomarkers for early cardiovascular risk assessment.Read full original descriptionShow less
Endothelial Extracellular Vesicles as Biomarkers of Blood Pressure-Induced Endothelial Activation in Children With Newly Diagnosed Untreated Primary Hypertension
Childhood hypertension is associated with early endothelial dysfunction and an increased risk of future cardiovascular disease. Endothelial extracellular vesicles (EEVs) have emerged as promising biomarkers of endothelial activation; however, their role in pediatric hypertension remains poorly understood. This observational case-control study aims to compare circulating EEV concentrations between normotensive children and children with newly diagnosed, untreated primary hypertension. The study will also investigate the associations between EEV levels, blood pressure, microvascular endothelial function assessed by laser Doppler flowmetry, and circulating biomarkers of endothelial activation. The findings may improve understanding of endothelial injury in pediatric hypertension and support the development of non-invasive biomarkers for early cardiovascular risk assessment.
Inclusion: Children and adolescents aged 6-17 years; Written informed consent from a parent or legal guardian and assent from the participant when appropriate; Normotensive status or newly diagnosed, previously untreated primary hypertension according to current pediatric hypertension guidelines; Ability to comply with study procedures.
Exclusion: Previous antihypertensive treatment; Use of medications known to affect endothelial function; Secondary hypertension; Congenital heart disease or other significant cardiovascular disease; Diabetes mellitus; Chronic kidney disease; Autoimmune or chronic inflammatory disease; Acute infection at the time of enrollment; Malignancy; Inability to comply with study procedures.